Moderna is the second company to announce preliminary results from the final phase of the corona vaccine trial. However, it still takes a long time for the vaccine to become widely available.
The pharmaceutical company Moderna announced Monday that based on a preliminary look at the results of an extensive and ongoing trial, their coronavirus vaccine is 94.5% effective. According to researchers, the results are better than they imagined; But the vaccine will probably not be widely available until spring. The study data were analyzed by members of the Independent Vaccine Safety Monitoring Board, appointed by the US National Institutes of Health.
Moderna is the second company to announce the end of a catastrophic virus with preliminary data on the Corona vaccine’s success, which has so far infected more than 53 million people worldwide and killed more than 1.2 million. Last week, Pfizer, in partnership with Biotech, was the first company to report more than 90% success of the Corona vaccine.
Pfizer and Moderna are the first vaccine manufacturers to release preliminary data from end-stage trials. Still, ten other companies in Australia, Britain, China, India, and Russia are also conducting third-stage trials in the global vaccine competition. Also, more than 50 other vaccine candidates are in the early stages of testing.
The Pfizer and Moderna vaccines are more than 90 percent effective, while the US Food and Drug Administration says Covid 19 vaccines must be at least 50 percent effective to be licensed. The researchers tested the vaccine’s efficacy by vaccinating some participants in the trial, giving the drug to others, and then monitoring the two groups to see how many people became ill. In the Maderna study, 95 people became infected with the coronavirus, of which only five were vaccinated and 90 received medication. Also, 11 seriously ill patients out of 95 were all recipients of the drug. Statistically, this difference between the two groups is very significant.
Based in Cambridge, Massachusetts, Moderna developed the corona vaccine in collaboration with researchers from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases. In an interview, Dr. Anthony Fauci, director of the institute, described the 94.5% effectiveness as very impressive and surprising. Moderna CEO Stephen Bensel also said that the results provided the first clinical confirmation that their vaccine could prevent Covid 19 disease, including its severe form.
Pfizer and Moderna presented their findings in news releases, and no peer-reviewed articles have yet been published. The companies have also not yet released detailed information that will allow foreign experts to evaluate their claims. Hence, the results cannot be considered definitive; Because studies are not yet complete, the numbers on the vaccine’s effectiveness may change in the future.
Pfizer and Moderna have opened the door to a whole new path to rapid vaccine development. Both companies use genetic material called messenger RNA, which instructs the human body to copy the coronavirus spike protein. The immune system then learns to defend against this protein. Gene-based vaccines have long been promising for the future of vaccine development, But they were never approved for human use. The successful results of Moderna and Pfizer vaccines are a promising sign of the effectiveness of this method.
One concern with vaccines is that they are too fragile and need to be kept at a cold temperature, But Moderna announced today that their corona vaccine could be stored in the refrigerator (between 2 and 8 degrees Celsius) for up to 30 days; Pfizer and Bionatech vaccine should be kept at a temperature of minus 70 degrees Celsius. This will make the Moderna vaccine easier to store and distribute.
Moderna says it will produce 20 million doses of the vaccine by the end of this year and between 500 million and 1 billion doses by 2021. However, since the company’s vaccine is a second type, each person must receive two doses to be fully vaccinated.